Escuche esta historia
--:--
2:25
Ómicron: Pfizer and Moderna work on a vaccine for the new variant
Pharmaceutical organizations have reported that they are preparing new antibodies against COVID-19 and hope to have them designed for this year.
The CEO of Pfizer, Albert Bourla, revealed to the television channel Consumer News and Business Channel, (CNBC), that the assembly of this new antibody is due to the fact that many nations would be interested in having them accessible as soon as possible. It is very possible that it will be prepared in March of this year.
Bourla stated that this new vaccine seeks greater invulnerability against omicron, although in any case the protection against different variations would be effective.
The counselor added that the goal is to achieve something that has greater protection, especially against infection. For now, avoiding hospitalizations and serious symptoms is the purpose of current vaccines, as long as the third dose has been received.
Likewise, Stephane Bancel, delegate of the Modern Organization, assured the CNBC channel that they are also working on the process of a new booster for their vaccine, explicitly intended to protect against omicron variation.
In addition, he reported that they hope to have it accessible after September of this year, and that from now on they are in talks with wellness specialists from around the planet, to choose the best technique. The goal is to have it ready by fall 2022.
He indicated that they have concluded agreements with countries such as the United Kingdom, Switzerland and South Korea.
Scientific investigations regarding immunizations against Covid-19 have found that they have indeed significantly decreased the possibility of experiencing a serious case.
Novartis Anticovid Treatment
Other pharmaceutical organizations are also creating more drugs to fight COVID-19 and thus increasing the list of options to control the infection.
The Swiss pharmaceutical company, Novartis, made an announcement in which it assured that they have carried out phase 2 trials and have obtained positive results, and that it is medically capable of combating all variants, including omicron.
Ensovibep, is the name of the treatment, which is administered intravenously.
This showed a decrease in viral load after eight days. The preliminaries were carried out in patients with severe cases of COVID-19, without the need for hospitalization, who were treated in different health centers.
